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ABSTRACT
Background. Many publications report the prevalence of
chronic kidney disease (CKD) in the general population. Com-
parisons across studies are hampered as CKD prevalence esti-
mations are inﬂuenced by study population characteristics
and laboratory methods.
Methods. For this systematic review, two researchers independ-
ently searched PubMed,MEDLINE and EMBASE to identify all
original research articles that were published between 1 January
2003 and 1 November 2014 reporting the prevalence of CKD in
the European adult general population. Data on study method-
ology and reporting of CKD prevalence results were independ-
ently extracted by two researchers.
Results.We identiﬁed 82 eligible publications and included 48
publications of individual studies for the data extraction. There
was considerable variation in population sample selection. The
majority of studies did not report the sampling frame used, and
the response ranged from 10 to 87%. With regard to the assess-
ment of kidney function, 67% used a Jaffe assay, whereas 13%
used the enzymatic assay for creatinine determination. Isotope
dilution mass spectrometry calibration was used in 29%. The
CKD-EPI (52%) and MDRD (75%) equations were most
often used to estimate glomerular ﬁltration rate (GFR). CKD
was deﬁned as estimated GFR (eGFR) <60 mL/min/1.73 m2
in 92% of studies. Urinary markers of CKD were assessed in
60% of the studies. CKD prevalence was reported by sex and
age strata in 54 and 50% of the studies, respectively. In publica-
tions with a primary objective of reporting CKD prevalence,
39% reported a 95% conﬁdence interval.
Conclusions. The ﬁndings from this systematic review showed
considerable variation in methods for sampling the general
population and assessment of kidney function across studies re-
porting CKD prevalence. These results are utilized to provide
recommendations to help optimize both the design and the re-
porting of future CKD prevalence studies, which will enhance
comparability of study results.
Keywords: CKD, CKD-EPI equation, epidemiology, MDRD,
systematic review
INTRODUCTION
Chronic kidney disease (CKD) is considered to be a major pub-
lic health problem [1]. CKD has an important impact both at
the patient level, by decreasing the quality of life and life expect-
ancy, and at the population level, by increasing health-care costs
and the demand for health-care services.
Since CKDprevalence estimation is central to CKDmanage-
ment and prevention planning at the population level [2], it is
not surprising that many publications report CKD prevalence
in the general population. It is common research practice to
put study results into context by comparing them with previous
publications to identify the regional CKD burden, assessing the
impact on regional health-care systems and for tailoring
preventive strategies to communities. In the case of CKD pre-
valence, such comparisons are likely hampered as CKD
prevalence estimations are inﬂuenced by study population
characteristics and by the methods used to assess kidney func-
tion [3, 4]. To realistically compare CKD prevalence across dif-
ferent population-based studies, methodological factors should
be taken into account.
The purpose of this systematic literature review was to (i)
identify all studies reporting on CKD prevalence in the Euro-
pean adult general population and (ii) to describe the method-
ology used in these studies. The ﬁndings from this review are
utilized to provide recommendations that may help investiga-
tors to optimize both the design and the reporting of future
CKD prevalence studies, which will enhance comparability of
results across studies.
METHODS
Search strategy
A systematic literature search was performed in PubMed,
MEDLINE and EMBASE to identify all original research
articles reporting the prevalence of CKD in the adult general
population. As Kidney Disease Outcomes Quality Initiative
(KDOQI) published a guideline on CKD deﬁnition [5] in
2002, we included articles published between 1 January 2003,
which is one year after the publication of the KDOQI guideline,
and 1 November 2014, when our search was last updated. The
database-speciﬁc search queries are presented in the Supple-
mentary data, Appendix S1. Additionally, the representatives
of national kidney foundations, renal registries and expert
nephrologists in 39 European countries were asked to provide
information on any relevant studies.
Study selection
Publications that presented original research, were designed
to select a representative sample of a European adult general
population and reported a CKD prevalence estimate were in-
cluded. We excluded studies that ended subject recruitment
prior to 1996 and studies lacking glomerular ﬁltration
rate (GFR) estimation based on serum creatinine. Cystatin
C-based estimated GFR (eGFR) will lead to higher CKD preva-
lence estimates than creatinine-based eGFR [6]. For the sake of
comparability, we chose not to include publications that solely
reported cystatin C-based prevalence estimates. No language
restrictions were applied. The literature search was done by
two investigators (KB, ED). Any study that was judged relevant
on the basis of its title was retrieved in abstract form, and if rele-
vant, in full-text form. Any doubt about eligibility was resolved
by discussion with another investigator (VS).
Data extraction
All publications were initially seen by one investigator (KB)
and then independently reassessed by two additional investiga-
tors (ED for the ﬁrst half and AK for the second half ). For
studies with multiple eligible publications, we selected the pub-
lication with a primary objective of reporting CKD prevalence
or the most recent publication. Publications were assessed on
method of population selection, which included the sampling
frame (i.e. source used to identify subjects) and the sample
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design (i.e. the method of sample selection). Additionally, we
extracted information on the assessment of kidney function.
The extracted data were categorized as follows:
(i) Creatinine assay was categorized as enzymatic, Jaffe, modi-
ﬁed Jaffe, compensated Jaffe or unclear. The Jaffemethod is
known to suffer from interference by other substances [7],
and multiple adaptations have been implemented to im-
prove method speciﬁcity [7]. The compensated and modi-
ﬁed Jaffe assays were developed to improve method
speciﬁcity and minimize susceptibility of interfering sub-
stances [7]. The compensated Jaffe method is the use of a
manufacturer-speciﬁc mathematical compensation [8].
The modiﬁed Jaffe assays are modiﬁcations of the method
such as deproteinization of the sample prior to analysis or
the addition of potassium ferricyanide [9].
(ii) Calibration was categorized as calibrated to the standar-
dized isotope dilution mass spectrometry (IDMS) or ca-
librated by another method or calibrator.
(iii) Urinary albumin assay was categorized as dipstick, im-
munoassay (including both nephelometric and turbido-
metric immunoassays) or other.
(iv) The CKD deﬁnition was categorized as use of the KDOQI
2002 deﬁnitions [5] or use of other deﬁnitions. Use of
chronicity criterion, i.e. persistence of albuminuria or de-
creased eGFR for at least 3 months, was assessed.
(v) Ethnicity reporting was categorized as ‘yes’ if publication
reported collection of ethnicity data and as ‘no’ if ‘ethni-
city’ data were not collected or if those were not reported.
Finally, we extracted the following data on presentation of CKD
prevalence results: the use of 95% conﬁdence intervals (95%CI),
the use of standardization of the prevalence estimate to a reference
population and the presentation of results by age group and sex. If
CKDprevalencewas not themain focus of the publication, the use
of 95%CI was rated as not applicable (n/a). The data extraction
form is shown in the Supplementary data, Appendix S2.
RESULTS
Study selection
Figure 1 shows the selection process of inclusion and exclu-
sion of publications in a ﬂow chart. We retrieved 2000
F IGURE 1 : Flow chart of publication selection.
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individual publications of which only one study was solely iden-
tiﬁed through contacting national representatives. A total of
1842 publications were excluded based on title or abstract.
Twenty-ﬁve publications were excluded as the study was not de-
signed to select a representative sample of the general popula-
tion, 9 studies were excluded as they ended recruitment prior to
1996 and 42 publications were excluded for not presenting a
CKD prevalence estimate. Eighty-two publications fulﬁlled
the inclusion criteria. Eighteen studies had multiple publica-
tions, highlighting various aspects of CKD (overall 34 publica-
tions). Finally, we included 48 publications of individual studies
for the data extraction.
Data extraction
Table 1 describes the method of general population sample
selection including the response per study. Details on the
laboratory assessment of kidney function, the CKD deﬁnition
used and on the reporting of CKD prevalence are presented
in Table 2.
Population selection. All studies combined described a total
of 247 342 subjects. The size of the study population ranged
from 328 to 65 181 subjects. Twenty-three studies (48%) in-
cluded virtually the entire age range of the adult population.
The remaining (n = 25; 52%) studies restricted the recruitment
of subjects to a higher age range.
Four studies (8%) used census data as the sampling frame to
identify eligible study subjects. More than half of the studies
(n = 26; 54%) did not report the sampling frame used. Fourteen
studies (29%) were designed to select their population by age and
sex stratiﬁcation, and 12 studies (25%) selected a random sample.
Ten studies (21%) did not provide details on the sample design,
six of which referred to previous publications for more details.
The response was given in 31 studies (65%) and ranged from
10 to 87%. Of the 17 studies that did not report a response, 2
studies referred to a previous publication for details regarding
responders and non-responders.
Assessment of kidney function. Serum creatinine was deter-
mined by Jaffe assay in themajority of studies (n = 32; 67%) and
by enzymatic assay in six (13%) studies. Only few creatinine as-
says were calibrated to IDMS (n = 14; 29%). Urinary markers
for kidney disease were assessed in 29 studies (60%), 15 of
which (31%) used immunoassay to detect albuminuria. Seven
studies (15%) used dipsticks to identify proteinuria, with con-
ﬁrmation of albuminuria by immunoassay in four studies (8%).
CKD deﬁnition. Almost all studies (n = 44; 92%) deﬁned
CKD as eGFR below 60 mL/min/1.73 m2. Eighteen studies
(38%) reported CKD prevalence deﬁned as eGFR below 60
mL/min/1.73 m2 and/or the presence of albuminuria >30 mg/g,
and 15 studies (32%) reported CKD prevalence deﬁned as albu-
minuria >30 mg/g. Although 10 studies (21%) additionally
reported CKD according to another deﬁnition, only one study ex-
clusively reported a CKD prevalence not deﬁned by KDOQI.
The Modiﬁcation of Diet in Renal Disease (MDRD) equa-
tion for unstandardized creatinine was used to estimate GFR
in 22 studies (46%), and the MDRD equation for standardized
creatinine was used in 14 studies (29%). Twenty-ﬁve studies
(52%) used the CKD Epidemiology Collaboration (CKD-EPI)
equation, and nine studies (19%) used the Cockcroft and
Gault equation. Even though both the CKD-EPI and MDRD
equations include an ethnicity variable, only 18 studies (38%)
reported collecting ethnicity data. Eleven studies (23%) did
not indicate whether ethnicity data were collected.
Reporting results. CKD prevalence reporting was the main
objective in 36 publications, of which 39% reported a 95%CI.
An age- and sex-standardized prevalence was reported in 12
studies (25%), of which 9 standardized to their national popu-
lation. Although two studies standardized their population to
the US population, only one study standardized to the Euro-
pean population. The presentation of CKD prevalence by strata
was done by 31 studies, and these studies presented the CKD
prevalence stratiﬁed per risk factor, mostly by age (n = 24;
50%) and by sex (n = 26; 54%).
DISCUSSION
We assessed 48 publications, published between 1 January 2003
and 1 November 2014, reporting CKD prevalence for the adult
general population in 20 European countries. The results of this
systematic literature review revealed considerable variation in
general population sample selection methods and assessment
of kidney function across studies. Moreover, often a clear de-
scription of the methods used was lacking, and the reporting
of CKD prevalence was heterogeneous. These factors may
have considerable inﬂuence on the prevalence estimates of
CKD and need to be taken into account to allow comparison
of CKD prevalence across studies.
Population sample selection
Although we restricted our search to studies that were
designed to be representative of the general population, we
observed great heterogeneity in population sample selection
methods. Part of this variation was found in the sampling
frame used to identify contact details of eligible subjects. The
sampling frame should ideally include the entire target popula-
tion [58], which in this case is the entire general population.
National census or population registry data are ideal for sam-
pling the general population; in principle, these should include
all inhabitants of a country or region. However, general popu-
lation surveys are typically limited to community-dwelling
subjects who are physically and mentally capable to participate
in such studies. At old age, a substantial proportion of those
with age-related chronic diseases such as CKD may no longer
fulﬁll these inclusion criteria, which may lead to substantial
underestimation of the true prevalence of such diseases. In
such circumstances, depending on the health system or country,
general practitioner list- or registry-based approaches might be
required to provide more valid estimates of true prevalence.
Additionally, there existed great variation in sample design.
For example, some studies ﬁrst performed stratiﬁcation of
population by age and sex, whereas others invited all inhabi-
tants in the selected region. Both the sampling frame and
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Table 1. Description of the method of general population sample selection per study
Author (Ref.) Study name Country Time period Number of
subjects, N
Age
range
Sampling frame Sample design Response, %
Aumann et al. [10] SHIP Germany 2001–6 2830 25–88 Not speciﬁeda Multistage sampling 69
Bongard et al. [11] MONA LISA France 2006–7 4727 35–75 Electoral rolls Age and sex stratiﬁed Not given
Browne et al. [12] SLAN Ireland 2007 1098 45+ Other (Geo directory) Multistage random sampling: by area and
region
66
Capuano et al. [13] VIP Italy 1998–99 and
2008–9
2400 25–74 Electoral rolls Age and sex stratiﬁed Not given
Christensson et al. [14] GAS Sweden 2001–4 2815 60–93 Census Stratiﬁed, age, sex and urban/rural
location
60
Chudek et al. [15] PolSenior Poland 2007–11 3793 65+ Not speciﬁeda Not speciﬁeda 32
Cirillo et al. [16] Gubbio Population Study Italy Not speciﬁed 4574 18–95 Not speciﬁeda Not speciﬁeda Not givena
Codreanu et al. [17] Early Detection and
Intervention Program for
Chronic Renal and
Cardiovascular Disease in the
Rep Moldova
Moldova 2006–7 973 18–77 Not speciﬁed Not speciﬁed Not given
De Nicola et al. [18] CARHES Italy 2008 4077 35–79 Electoral rolls Age and sex stratiﬁed 45
Delanaye et al. [19] Belgium 2008–9 1992 45–75 Not speciﬁed Voluntary nature Not given
Donfrancesco et al. [20] MATISS Italy 1993–96 2924 20–79 Electoral rolls Age- and sex-stratiﬁed random sample 60
Formiga et al. [21] Octabaix Spain 2009 328 85 Not speciﬁeda Not speciﬁeda Not given
Fraser et al. [22] HSE England 2009–10 5799 16+ Other (address list) Random two-stage sample Not givena
Gambaro et al. [23] INCIPE Italy 2006 3629 40+ General practitioner list Random sample 62
Gianelli et al. [24] InChianti Italy 1998–2000 676 65+ Not speciﬁed Multistage stratiﬁed random sample Not given
Goek et al. [25] KORA Germany 1999–1 1104 54–75 Not speciﬁed Not speciﬁed Not given
Gu et al. [26] FLEMENGHO Belgium 2005–10 797 18–89 Not speciﬁed Not speciﬁed 78
Guessous et al. [27] Swiss Study on Salt intake Switzerland 2010–11 1145 15+ Other (phone directory) Age- and sex-stratiﬁed random sample 10
Hallan et al. [28] HUNT 2 Norway 1995–97 65 181 20+ Not speciﬁed All inhabitants 70
Hernandez et al. [29] IMAP Spain 2007 2270 18–80 Not speciﬁeda Random sample Not given
Juutilainen et al. [30] FINRISK Finland 2002 and 2007 11 277 25–74 Census Age- and sex-stratiﬁed random sample 71 in men
74 inwomen
Lieb et al. [31] MONICA/KORA Germany Not speciﬁed 1187 25–74 Not speciﬁed Age- and sex-stratiﬁed random sample 71
Meuwese et al. [32] Leiden 85 + study Netherlands 1997–99 558 85 Not speciﬁed All in birth cohort 87
Nitsch et al. [33] BWHHS UK 1999–2001 3851 60–79 Not speciﬁeda Random sample 60
Nitsch et al. [34] SAPALDIA 2 Switzerland 1991 and 2002 6317 18+ Not speciﬁeda Random sample 73
Otero et al. [35] EPIRCE Spain 2004–8 2746 20+ Census Age-, sex- and region-stratiﬁed random
sample
43
Pani et al. [36] SardiNIA study Italy 2001– 4471 14–102 Not speciﬁeda Not speciﬁeda 56
Pattaro et al. [37] MICROS Italy 2002–3 1199 18+ Not speciﬁeda Not speciﬁeda Not given
Ponte et al. [38] CoLaus Switzerland 2003–6 5921 35–75 Population registry Random sample 41
Redon et al. [39] PREV-ICTUS Spain 2005 6419 60+ General practitioner lists Random sample 72
Robles et al. [40] HERMEX Spain Not speciﬁed 2813 25–79 Other (health-care system
database)
Age- and sex-stratiﬁed random sample 83
Roderick et al. [41] MRC Older Age Study UK 1994–99 13 179 75+ General practitioner list Practices stratiﬁed by mortality score and
deprivation score
73
Rothenbacher et al. [42] ActiFE Ulm Germany 2009–10 1471 65+ Census Random sample 20
Rutkowski et al. [43] PolNef Poland 2004–5 2476 n/a Other (address list) Random sample 26
Sahin et al. [44] Turkey 2005 1079 18–95 Not speciﬁed Age, sex and region stratiﬁed Not given
Schaeffner et al. [45] BIS Germany 2011 570 70+ Not speciﬁeda Not speciﬁeda Not given
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sample design inﬂuence the response and non-response bias
[58], which in turn may inﬂuence the representativeness of
the resulting sample for the general population and conse-
quently of the CKD prevalence estimate. Collecting informa-
tion on non-responders may help to assess the possibility and
likely direction of non-response bias [58].
Assessment of kidney function
Serum creatinine and albuminuria measurements. There
was great variation in the laboratory methods used in studies
that reported details of those methods, especially in the calibra-
tion of serum creatinine. Differences in creatinine assays are im-
portant to take into account in CKD prevalence comparisons,
as Jaffe methods overestimate serum creatinine and therefore
overestimate CKD prevalence [59]. In 2006, IDMS standardiza-
tion has been implemented to reduce the systematic bias in
creatinine determination and to increase inter laboratory com-
parability [7]. The publications that clearly reported the use of
IDMS standardization were only published in 2010 or later.
Ethnicity. In equations used to estimate GFR, like MDRD
and CKD-EPI, the variable ‘ethnicity’ is included to adjust for
ethnicity-speciﬁc differences. Ethnicity may, therefore, inﬂu-
ence CKD prevalence estimates; even so, less than half of the
publications reported collection of ethnicity data. Since in
most European countries the vast majority of the European
population is Caucasian, the lack of ethnicity data is unlikely
to inﬂuence the CKD prevalence of most countries. In the fu-
ture, however, the proportion of Caucasian subjects in the
European populationmay change, making the collection of eth-
nicity data more important.
CKD deﬁnition. Despite the KDOQI guideline on CKD that
was published in 2002 [5] and updated by Kidney Disease Im-
proving Global Outcomes (KDIGO) in 2012 [60], we observed
great variation in the deﬁnition of CKD, both in eGFR equa-
tions used and in cut-off values for both eGFR and albumin-
uria. For future studies, it is advisable to report CKD as
recommended in the updated KDIGO guideline, including
six eGFR categories and three albuminuria categories, as this
classiﬁcation allows presentation by mortality and progression
risk [61]. The chronicity criterion was never used, mainly be-
cause follow-up data on serum creatinine were not collected.
In more recent studies, CKD was most commonly deﬁned
using the CKD-EPI equation, as recommended by KDOQI [5].
Reporting methods
A clear description of the population sample selectionmeth-
ods and assessment of kidney functionmay facilitate amore fair
comparison of CKD prevalence across studies. Studies should,
therefore, preferably report this in detail in the method section
of their publication. Unfortunately, many studies did not report
the sampling frame used. In addition, information about bio-
logical sample collection (e.g. nature of collecting procedure,
participants conditions, time between sampling and further
processing) and sample storage conditions (duration of storage,
thawing cycles, etc.) should also be reported [62].
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Table 2. Laboratory assessment of kidney function, CKD deﬁnition used and details on the reporting of CKD prevalence per study
Author (Ref.) Creatinine assay IDMS Albuminuria CKD deﬁnition eGFR equation Ethnicity CI Age and sex
standardized
Stratiﬁed prevalence
Aumann et al. [10] Jaffe Other n/a 2 CKD-EPI + other Yes n/a No Yes: other
Bongard et al. [11] Jaffe No n/a 2 MDRD (old) No Yes Yes to national pop. No
Browne et al. [12] Modiﬁed Jaffe Yes Other 1 + 2 CKD-EPI + new MDRD No Yes Yes to national pop. Yes: age, sex and
other
Capuano et al. [13] Modiﬁed Jaffe No n/a 2 CG No No Yes to national pop. Yes: age, sex and
other
Christensson et al. [14] Unclear Other n/a Other CKD-EPI, MDRD
(old) + CG
Yes No No Yes: age and sex
Chudek et al. [15] Jaffe Unclear If dipstick −→
immunoassay
1 + 2 + 3 CKD-EPI No No No Yes: age, sex and
other
Cirillo et al. [16] Modiﬁed Jaffe No Immunoassay 2 MDRD (old) Yes Yes forN
Not for
%
Yes to national pop. Yes: age and sex
Codreanu et al. [17] Unclear No Other 2 + 3 MDRD (old) No No No Yes: age, sex and
other
De Nicola et al. [18] Enzymatic Yes Immunoassay 1 + 2 + 3 CKD-EPI No Yes No No
Delanaye et al. [19] Compensated Jaffe Yes n/a 2 CKD-EPI + new MDRD No No No Yes: sex
Donfrancesco et al. [20] Enzymatic Yes n/a 2 CKD-EPI No No No Yes: sex
Formiga et al. [21] Compensated Jaffe No n/a 2 MDRD (old) No No No No
Fraser et al. [22] Enzymatic Yes Not speciﬁed 1 + 2 + 3 + other CKD-EPI + new MDRD Yes No Unclear Yes: other
Gambaro et al. [23] Modiﬁed Jaffe Other If dipstick +→
immunoassay
1 + 2 + 3 CKD-EPI Yes Yes Yes to US pop. Yes: age, sex and
other
Gianelli et al. [24] Modiﬁed Jaffe No n/a 2 MDRD (old) and CG No No No No
Goek et al. [25] Compensated Jaffe Unclear n/a 2 CKD-EPI No n/a No No
Gu et al. [26] Modiﬁed Jaffe Unclear Not speciﬁed 2 CKD-EPI +MDRD (old) No No No No
Guessous et al. [27] Compensated Jaffe Unclear Unclear 1 CKD-EPI Yes n/a No No
Hallan et al. [28] Jaffe Other Immunoassay 1 + 2 + 3 New MDRD Yes Yes Yes to national + US
pop.
Yes: age, sex and
other
Hernandez et al. [29] Not speciﬁed Unclear Not speciﬁed 1 + other CKD-EPI Yes n/a No Yes: other
Juutilainen et al. [30] Enzymatic Yes n/a 2 + other CKD-EPI + new MDRD No no No Yes: age and sex
Lieb et al. [31] Enzymatic No Immunoassay 3 + other MDRD (old) No n/a No No
Meuwese et al. [32] Jaffe No n/a 2 CKD-EPI +MDRD (old) No n/a No No
Nitsch et al. [33] Modiﬁed Jaffe Other n/a 2 MDRD (old) Yes n/a No Yes: other
Nitsch et al. [34] Jaffe Other n/a 2 MDRD (old) and CG Yes Yes No Yes: age and sex
Otero et al. [35] Unclear Unclear Unclear 1 + 2 MDRD (old) Yes Yes Yes to national pop. Yes: age, sex and
other
Pani et al. [36] Not speciﬁed Other Not speciﬁed 1 + 2 + 3 CKD-EPI + new MDRD No Yes No Yes: age and sex
Pattaro et al. [37] Enzymatic Yes n/a 2 CKD-EPI, new
MDRD+ other
No Yes No Yes: age
Ponte et al. [38] Compensated Jaffe Yes Immunoassay 1 + 2 + 3 CKD-EPI + new MDRD Yes Yes No Yes: age and sex
Redon et al. [39] Jaffe Yes Immunoassay 2 CG No n/a No No
Robles et al. [40] Modiﬁed
Jaffe + enzymatic
No Dipstick 2 + other CKD-EPI + new MDRD Yes Yes Yes to EU pop. Yes: age and sex
Roderick et al. [41] Modiﬁed Jaffe Yes Immunoassay 2 + other MDRD (old) No Yes No Yes: age and sex
Rothenbacher et al. [42] Modiﬁed Jaffe No If dipstick +→
immunoassay
1 + 2 + 3 CKD-EPI + new MDRD No No No Yes: age and sex
Rutkowski et al. [43] Modiﬁed Jaffe Unclear n/a 1 + 2 + 3 MDRD (old) No No No No
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Sahin et al. [44] Enzymatic Yes Not speciﬁed 2 New MDRD No No No Yes: age, sex and
other
Schaeffner et al. [45] Unclear Unclear Immunoassay 2 CKD-EPI + other Yes n/a No No
Scheven et al. [46] Modiﬁed Jaffe Unclear If dipstick +→
immunoassay
1 + 2 + 3 CKD-EPI No n/a No* No
Stasevic et al. [47] Jaffe Yes Unclear 2 + 3 + other MDRD (old) No No No No
Stengel et al. [48] Jaffe Yesa Immunoassay 1 + 2 CKD-EPI + new MDRD No No No Yes: age and sex
Suleymanlar et al. [49] Not speciﬁed No Not speciﬁed 1 + 2 + 3 MDRD (old) Yes No Yes to national pop. Yes: age and sex
Tavira et al. [50] Modiﬁed Jaffe No n/a 2 MDRD (old) Yes n/a No No
Van Pottelbergh et al. [51] Modiﬁed Jaffe No Dipstick 2 MDRD (old) and CG No No No Yes: age and sex
Viktorsdottir et al. [52] Modiﬁed Jaffe No n/a 1 + 2 + 3 MDRD (old) and CG Yes No Yes to global pop. Yes: age and sex
Vinhas et al. [53] Jaffe Unclear Immunoassay 2 MDRD (old) No Yes Yes to national pop. Yes: age, sex and
other
Wasen et al. [54] Unclear Yes n/a 2 + other New MDRD and CG No No No Yes per sex
Wetmore et al. [55] Jaffe Other Dipstick 2 New MDRD and CG Yes No No No
Zambon et al. [56] Modiﬁed Jaffe No Immunoassay 2 + other CKD-EPI and MDRD (old) Yes n/a Yes to national pop. No
Zhang et al. [57] Modiﬁed Jaffe Other n/a 2 + other MDRD (old) No No No Yes: age, sex and
other
Albuminuria = method of albuminuria measurement; CKD deﬁnition 1 = eGFR below 60 mL/min/1.73 m2 and or the presence of albuminuria >30 mg/g (i.e. CKD Stages 1–5); 2 = eGFR below 60 mL/min/1.73 m2 (i.e. CKD Stages 3–5); 3 = albuminuria
>30 mg/g. Ethnicity = ‘yes’ if collection is reported; ‘no’ if not reported or not collected. CI, conﬁdence interval given for prevalence estimate; CG, Cockcroft and Gault equation; n/a, not applicable.
aIn order to standardize creatinine values, 1720 frozen serum samples were remeasured in a single laboratory with an IDMS-traceable enzymatic assay. Hereafter, equations relating the Jaffe and IDMS-traceable creatinine were developed to standardize all
baseline values as follows: ScrIDMS = 0.86 × ScrJaffe + 4.40. *Population corrected for sampling design (i.e. oversampling of albuminuria).
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Reporting results
Another observed difference was the presentation of the re-
sults on CKD prevalence estimates. Part of this variation is like-
ly explained by the fact that CKD prevalence was not the main
focus of 12 publications. However, even in publications with the
main focus on CKD prevalence, there was great variation in re-
porting. All studies did report unadjusted prevalence estimates,
yet they were mostly reported without a 95%CI. The reporting
of the 95%CI is necessary as it provides an indication of how
much uncertainty there is in the prevalence estimate.
Future studies should preferably report CKD prevalence
standardized to the European population to enable international
comparison, at least across Europe. In the case of regional pre-
valence estimates, additional standardization to the national
population is required for within-country comparison. This
standardization is essential when comparing CKDprevalence es-
timates from different countries or regions to avoid the inﬂuence
of differences in national or regional age and sex distributions.
European CKD Burden Consortium
In 2012, the European CKD Burden Consortium was estab-
lished, including both nephrologists and epidemiologists, to
enhance comparability of CKD prevalence across European
regions and countries.
Box 1 provides an overview of the methodology used by the
European CKD Burden Consortium to compare CKD preva-
lence results across different general population-based studies
in Europe. This methodology facilitates comparability by
providing a detailed description of the population selection
method and the response of each study to help assess represen-
tativeness of the study population sample. Additionally, the ﬁg-
ures and tables clearly show the serum creatinine method used
(i.e. Jaffe versus enzymatic) and whether IDMS calibration
standardization was used.
Furthermore, a uniform deﬁnition of CKD based on the
KDIGO guideline was established [60]. CKD was deﬁned as
the presence of albuminuria >30 mg/g and/or an eGFR of
<60 mL/min/1.73 m2 as calculated by the CKD-EPI equation.
The chronicity criterion was not applied, for none of the as-
sessed general population-based studies had this available.
The Consortium will additionally harmonize reporting of
results in their publications. All CKD prevalence estimates
will be presented as unadjusted rates and standardized to the
EU27 population of 2005 [63] and include a 95%CI. As the oc-
currence of CKD is associated with age and not all study popu-
lations cover the entire range of the adult population, the CKD
prevalence will also be presented for different age ranges, i.e.
20–44, 45–64, 65–74 and 75–84 years. Additionally, the preva-
lence estimates will be presented with stratiﬁcation for the pres-
ence of the following risk factors: diabetes, hypertension and
obesity. This stratiﬁcation is useful to determine if differences
in CKD prevalence are caused by differences in risk factor pres-
ence or differences in overall health status of the general popu-
lation. Whether disparities in CKD prevalence are explained by
important risk factors for CKD will guide policy makers to
focus on secondary or primary prevention.
Implications
This systematic literature review revealed considerable
variation in general population sample selectionmethods and as-
sessment of kidney function across studies. In addition, a clear
description of the methods used was often lacking, and the re-
porting of CKD prevalence was heterogeneous. The approach
of The European CKD Burden Consortium will not eliminate
the differences in population selection methods and laboratory
assessment of kidney function. However, the recommendations
regarding the reporting of both methods and results of CKD
prevalence studies may enhance comparability of CKD preva-
lence results across Europe and evenworldwide [64]. Our recom-
mendations may be used by investigators to optimize both the
design and the reporting of future CKD prevalence studies.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford
journals.org.
Box 1: Recommended methodology for comparison of
CKD prevalence results across general population-based
studies as used by European CKD Burden Consortium
Recommended tools Details
1. General population sampling
Sampling methods Describe:
– sampling frame, i.e. source used to identify
subjects
– sample design, i.e. method of subject
selection (e.g. age stratiﬁed, random)
Response Report the response in percentages
2. Assessment of kidney function
Serum creatinine assay Describe assay used, i.e. Jaffe or enzymatic
Albuminuria assay Describe assay used, e.g. immunoassay and
dipstick
IDMS calibration
standardization
Describe if IDMS calibration standardization
was used (yes/no)
CKD deﬁnition Use of the same deﬁnition of CKD:
CKD Stages 1–5:
eGFR < 60mL/min/1.73 m² calculated by the
CKD-EPI equation, and/or ACR > 30 mg/g.
CKD Stages 3–5:
eGFR < 60mL/min/1.73 m² calculated by
CKD-EPI equation.
3. Presentation of results
CKD prevalence
estimate
Report:
– unadjusted and adjusted CKD prevalence
(e.g. standardized to the EU27 population)
– 95%CI
CKD prevalence
estimate by strata
Report:
– stratiﬁed by age groups: 20–44, 45–64, 65–
74 and 75–84 years
– stratiﬁed by diabetic, hypertension and
obesity status
Serum creatinine
determination
Indicate in tables and ﬁgures which studies
use:
– Jaffe or enzymatic assay
– IDMS calibration standardization
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